| Characteristics | Group VE (n = 49) | Group E (n = 363) | Group Y (n = 384) | p; VE vs. E | p; VE vs. Y |
|---|
| Epidemiology | | | | | |
| Age (years old) | 82 (80–92) | 71 (65–79) | 57 (33–64) | < 0.01 | < 0.01 |
| Sex, male to female (%) | 80(39):20(10) | 83(301):17(62) | 84(321):16(63) | 0.56 | 0.48 |
| HBs-Ag positive (%) | 6 (3) | 19 (69) | 53 (205) | 0.02 | < 0.01 |
| HCV-Ab positive (%) | 35 (17) | 34 (122) | 21 (80) | 0.88 | 0.02 |
| Both HBs-Ag and HCV-Ab positive (%) | 0 (0) | 1 (5) | 3 (10) | 0.40 | 0.25 |
| NBNC (%) | 59 (29) | 46 (167) | 23 (89) | 0.08 | < 0.01 |
| Biochemical factors | | | | | |
| Child-Pugh score | 5.2 ± 0.5 | 5.2 ± 0.5 | 5.2 ± 0.5 | 0.50 | 0.38 |
| Platelets (104/mm3) | 18.4 ± 6.8 | 17.5 ± 10.8 | 17.0 ± 7.6 | 0.54 | 0.20 |
| PA (%) | 94.8 ± 13.5 | 92.5 ± 14.0 | 91.4 ± 13.9 | 0.28 | 0.10 |
| ChE (IU/l) | 230 ± 68 | 244 ± 71 | 262 ± 90 | 0.22 | 0.01 |
| Albumin (g/dl) | 3.9 ± 0.3 | 4.0 ± 0.4 | 4.1 ± 0.5 | 0.06 | 0.04 |
| ICGR15 (%) | 15.8 ± 8.2 | 16.7 ± 9.6 | 15.8 ± 11.5 | 0.56 | 0.94 |
| AFP (ng/ml) | 5.5 (0–60,961) | 10.6 (0–378,718) | 27.5 (1–5,986,980) | 0.05 | < 0.01 |
| PIVKA-II (mAU/ml) | 198 (10–217,422) | 181 (8–664,680) | 207 (2.3–928,799) | 0.95 | 0.98 |
| Tumor factors | | | | | |
| Tumor size (cm) | 6.4 ± 3.5 | 5.7 ± 4.1 | 6.1 ± 5.2 | 0.23 | 0.66 |
| Multiple tumor (%) | 31 (15) | 35 (128) | 38 (144) | 0.52 | 0.34 |
| Differentiation, poor (%) | 39 (19) | 37 (134) | 46 (175) | 0.80 | 0.36 |
| PVI (%) | 14 (7) | 21 (75) | 34 (131) | 0.29 | < 0.01 |
| HVI (%) | 14 (7) | 11 (41) | 14 (52) | 0.54 | 0.88 |
| Fibrosis, f3/f4 (%) | 16 (8) | 40 (146) | 55 (213) | < 0.01 | < 0.01 |
- VE very elderly group, E elderly group, Y young group, HBs-Ag HBs-antigen, HCV-Ab HCV-antibody, NBNC without HBV and HCV, PA prothrombin activity, ICGR15 indocyanine green retention rate at 15 min, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin K absence-II, PVI portal venous invasion, HVI hepatic venous invasion
